Check Cap Ltd (NASDAQ:CHEK) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus price target of $14.00 for the company and are predicting that the company will post ($0.53) EPS for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 98 out of 255 based on the ratings given to related companies.

Several research analysts have commented on CHEK shares. HC Wainwright set a $14.00 price objective on Check Cap and gave the company a “buy” rating in a research report on Wednesday, June 6th. Zacks Investment Research lowered Check Cap from a “buy” rating to a “hold” rating in a research report on Tuesday, July 24th.

A hedge fund recently bought a new stake in Check Cap stock. Renaissance Technologies LLC acquired a new stake in Check Cap Ltd (NASDAQ:CHEK) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 129,442 shares of the medical research company’s stock, valued at approximately $524,000. Renaissance Technologies LLC owned 8.09% of Check Cap at the end of the most recent reporting period. 17.41% of the stock is owned by institutional investors and hedge funds.

Check Cap stock traded up $0.06 during midday trading on Friday, reaching $4.05. The stock had a trading volume of 73,900 shares, compared to its average volume of 317,279. Check Cap has a twelve month low of $3.08 and a twelve month high of $24.00.

Check Cap (NASDAQ:CHEK) last released its quarterly earnings data on Friday, August 10th. The medical research company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. equities research analysts predict that Check Cap will post -2.6 EPS for the current year.

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

See Also: What is the NASDAQ?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.